Cytokinetics, Incorporated (CYTK) Financial Statements (2024 and earlier)

Company Profile

Business Address 350 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:554,700592,600704,400829,300867,664586,026
Cash and cash equivalents99,69268,639101,61665,582106,23893,631
Short-term investments439,547497,083562,346716,995761,426492,395
Other undisclosed cash, cash equivalents, and short-term investments15,46126,87840,43846,723  
Receivables2,4999851,0061472,2941,973
Other undisclosed current assets4,217(7,010)(24,777)(34,261)14,31714,251
Total current assets:561,416586,575680,629795,186884,275602,250
Noncurrent Assets
Operating lease, right-of-use asset79,92980,86681,80282,73775,07672,161
Property, plant and equipment75,61477,24878,85980,45380,30278,586
Long-term investments and receivables15,46826,87140,40646,70828,54410,668
Long-term investments15,46826,87140,40646,70828,54410,668
Other noncurrent assets8,1878,3398,1199,691  
Other undisclosed noncurrent assets     7,7648,052
Total noncurrent assets:179,198193,324209,186219,589191,686169,467
TOTAL ASSETS:740,614779,899889,8151,014,7751,075,961771,717
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities46,75044,03152,98969,70772,43363,302
Employee-related liabilities17,77512,522
Accounts payable13,79612,56117,35725,61114,42914,078
Accrued liabilities32,95431,47035,63244,09640,22936,702
Debt      
Other liabilities13,7375,8857,9682,0815,7821,760
Other undisclosed current liabilities17,23615,70114,26312,829(1,719)1,781
Total current liabilities:77,72365,61775,22084,61776,49666,843
Noncurrent Liabilities
Long-term debt and lease obligation60,88562,49264,11063,810177,949175,076
Long-term debt, excluding current maturities60,88562,49264,11063,81063,54462,344
Liabilities, other than long-term debt122,624124,454126,178127,9391,2471,444
Other liabilities4086258371,0441,2471,444
Operating lease, liability122,216123,829125,341126,895114,405112,732
Other undisclosed noncurrent liabilities918,183860,451853,327846,309836,246416,940
Total noncurrent liabilities:1,101,6921,047,3971,043,6151,038,0581,015,442593,460
Total liabilities:1,179,4151,113,0141,118,8351,122,6751,091,938660,303
Equity
Equity, attributable to parent(438,801)(333,115)(229,020)(107,900)(15,977)111,414
Common stock949494949385
Additional paid in capital1,537,3211,514,1691,489,8141,481,5901,438,1031,422,127
Accumulated other comprehensive loss(874)(1,458)(1,645)(3,590)(5,559)(4,494)
Accumulated deficit(1,975,342)(1,845,920)(1,717,283)(1,585,994)(1,448,614)(1,306,304)
Total equity:(438,801)(333,115)(229,020)(107,900)(15,977)111,414
TOTAL LIABILITIES AND EQUITY:740,614779,899889,8151,014,7751,075,961771,717

Income Statement (P&L) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Revenues3788674,6131,9572,51588,968
Gross profit:3788674,6131,9572,51588,968
Operating expenses(122,643)(122,916)(129,086)(128,987)(110,956)(99,842)
Operating loss:(122,265)(122,049)(124,473)(127,030)(108,441)(10,874)
Nonoperating income6,8396,7796,4255,9194,144864
Investment income, nonoperating    6,1074,100900
Interest and debt expense(7,136)(7,045)(6,961)(7,057)(6,804)(2,807)
Loss from continuing operations:(122,562)(122,315)(125,009)(128,168)(111,101)(12,817)
Loss before gain (loss) on sale of properties:(111,101)(12,817)
Other undisclosed net loss  (6,280)(9,212)  
Net loss:(122,562)(122,315)(131,289)(137,380)(111,101)(12,817)
Other undisclosed net loss attributable to parent (6,860)(6,322)  (31,209)(7,003)
Net loss available to common stockholders, diluted:(129,422)(128,637)(131,289)(137,380)(142,310)(19,820)

Comprehensive Income ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Net loss:(122,562)(122,315)(131,289)(137,380)(111,101)(12,817)
Other comprehensive income (loss) 5841871,945 (1,065)(905)
Other undisclosed comprehensive income (loss)   (2,721)  
Comprehensive loss:(121,978)(122,128)(129,344)(140,101)(112,166)(13,722)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(6,860)(6,322) 4,690(31,209)(7,003)
Comprehensive loss, net of tax, attributable to parent:(128,838)(128,450)(129,344)(135,411)(143,375)(20,725)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: